The US Food and Drug Administration has granted accelerated approval to Otarmeni, a gene therapy from Regeneron for hearing loss caused by faulty copies of a single gene called OTOF. According to the FDA, 80% of the 20 patients evaluable for efficacy experienced improved hearing, something the agency says is not expected in the natural course of the disease.
What happened
In its announcement today, the FDA said it “granted accelerated approval of Otarmeni to Regeneron Pharmaceuticals, Inc.” for hearing loss caused by biallelic variants in the OTOF gene. Biallelic means both copies of the gene, the one inherited from each parent, carry a harmful change.
The agency described the key efficacy result in one sentence: “Of the 20 patients who were evaluable for efficacy, 80% experienced improved hearing, which is not expected in the natural history of the disease without intervention.”
The speed of the review stands out. The FDA says approval came 61 days after filing, and that Otarmeni is the first gene therapy approved under the Commissioner’s National Priority Voucher program.
Regeneron added its own figures. The company said 42% of patients achieved normal hearing at 48 weeks, and that it will provide the therapy free to eligible patients in the United States. It also said OTOF hearing loss affects about 50 newborns a year in the U.S.
How it works
Every gene is a set of instructions for building something the body needs. In people with OTOF hearing loss, both copies of that one instruction are faulty, so the inner ear cannot do its job properly, even though the rest of the hearing system may be in place.
Gene therapy tries to fix the problem at the level of the instructions. The idea is to deliver a working version of the gene directly to the cells that need it. Think of a machine that arrives with one page missing from its manual: everything else is there, and the machine cannot run until someone slips the right page back in. Otarmeni is that missing page, delivered to the right place.
Getting there is the hard part. The inner ear is small and well protected, deep inside the skull. According to the FDA, Otarmeni is given as “a single dose per ear surgically into the cochlea,” the spiral-shaped hearing organ, using a catheter and an infusion pump. So this is a surgical procedure performed by specialists, not a simple injection.
By the numbers
| Item | Figure | Source |
|---|---|---|
| Patients evaluable for efficacy | 20 | FDA |
| Share with improved hearing | 80% | FDA |
| Patients with normal hearing at 48 weeks | 42% | Regeneron |
| Days from filing to approval | 61 | FDA |
| Approval pathway | Accelerated approval | FDA |
| US newborns affected each year | About 50 | Regeneron |
| Cost to eligible US patients | Free | Regeneron |
Why it matters
For the first time, a gene can be delivered into the inner ear to restore hearing in children born deaf because of a single faulty gene. That is a meaningful proof that gene therapy can work in an organ that is hard to reach.
What caught my attention is the phrase the FDA chose: improvement that “is not expected in the natural history of the disease.” That comparison with the expected course of the condition is what gives the 80% figure its weight, since children with this form of hearing loss would not be expected to improve on their own.
It is equally important to be clear about the limits. Otarmeni is only for hearing loss caused by OTOF variants. It is not a treatment for deafness in general, and it does not apply to the many other causes of hearing loss. The two headline numbers also come from different sources and measure different things: the FDA’s 80% refers to improved hearing, while Regeneron’s 42% refers to reaching normal hearing at 48 weeks. And the group is small, 20 evaluable patients, which is typical for a very rare condition but still a small base.
In my view, the free access pledge for eligible U.S. patients matters almost as much as the science, because gene therapies are often out of reach for families even after approval.
What comes next
Accelerated approval is a specific pathway. It means continued approval may depend on confirmatory evidence, so Regeneron will need to keep showing that the benefit holds. For families, the practical next step is diagnosis: only patients whose hearing loss is confirmed to come from OTOF variants can be considered. Any decision about treatment belongs to families and their medical team, and nothing here is medical advice.
Sources
- US Food and Drug Administration, press announcement on the first gene therapy for genetic hearing loss, approved under the National Priority Voucher program, 23 April 2026, https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher
- Regeneron, press release on the FDA approval of Otarmeni, 23 April 2026, https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only